Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
Condition: Malignant Melanoma Stage III Interventions: Drug: Domatinostat; Drug: Nivolumab; Drug: Ipilimumab Sponsors: The Netherlands Cancer Institute; 4SC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials